Literature DB >> 22078173

Alliance for aging research AD biomarkers work group: structural MRI.

Clifford R Jack1.   

Abstract

Biomarkers of Alzheimer's disease (AD) are increasingly important. All modern AD therapeutic trials employ AD biomarkers in some capacity. In addition, AD biomarkers are an essential component of recently updated diagnostic criteria for AD from the National Institute on Aging--Alzheimer's Association. Biomarkers serve as proxies for specific pathophysiological features of disease. The 5 most well established AD biomarkers include both brain imaging and cerebrospinal fluid (CSF) measures--cerebrospinal fluid Abeta and tau, amyloid positron emission tomography (PET), fluorodeoxyglucose (FDG) positron emission tomography, and structural magnetic resonance imaging (MRI). This article reviews evidence supporting the position that MRI is a biomarker of neurodegenerative atrophy. Topics covered include methods of extracting quantitative and semiquantitative information from structural MRI; imaging-autopsy correlation; and evidence supporting diagnostic and prognostic value of MRI measures. Finally, the place of MRI in a hypothetical model of temporal ordering of AD biomarkers is reviewed.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22078173      PMCID： PMC3661287          DOI： 10.1016/j.neurobiolaging.2011.09.011

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN： 0197-4580            Impact factor:   4.673


  82 in total

1.  Classification of structural images via high-dimensional image warping, robust feature extraction, and SVM.

Authors:  Yong Fan; Dinggang Shen; Christos Davatzikos
Journal:  Med Image Comput Comput Assist Interv       Date:  2005

2.  Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects.

Authors:  John G Csernansky; Julia Hamstra; Lei Wang; Daniel McKeel; Joseph L Price; Mokhtar Gado; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2004 Oct-Dec       Impact factor: 2.703

3.  Conversion from subtypes of mild cognitive impairment to Alzheimer dementia.

Authors:  P Fischer; S Jungwirth; S Zehetmayer; S Weissgram; S Hoenigschnabl; E Gelpi; W Krampla; K H Tragl
Journal:  Neurology       Date:  2007-01-23       Impact factor: 9.910

4.  Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.

Authors:  D P Devanand; G Pradhaban; X Liu; A Khandji; S De Santi; S Segal; H Rusinek; G H Pelton; L S Honig; R Mayeux; Y Stern; M H Tabert; M J de Leon
Journal:  Neurology       Date:  2007-03-13       Impact factor: 9.910

5.  Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.

Authors:  K Ranga Rama Krishnan; H Cecil Charles; P Murali Doraiswamy; Jacobo Mintzer; Richard Weisler; Xin Yu; Carlos Perdomo; John R Ieni; Sharon Rogers
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

6.  Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.

Authors:  Shannon L Risacher; Andrew J Saykin; John D West; Li Shen; Hiram A Firpi; Brenna C McDonald
Journal:  Curr Alzheimer Res       Date:  2009-08       Impact factor: 3.498

7.  Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage.

Authors:  Prashanthi Vemuri; Jennifer L Whitwell; Kejal Kantarci; Keith A Josephs; Joseph E Parisi; Maria S Shiung; David S Knopman; Bradley F Boeve; Ronald C Petersen; Dennis W Dickson; Clifford R Jack
Journal:  Neuroimage       Date:  2008-05-20       Impact factor: 6.556

8.  Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.

Authors:  K B Walhovd; A M Fjell; J Brewer; L K McEvoy; C Fennema-Notestine; D J Hagler; R G Jennings; D Karow; A M Dale
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-14       Impact factor: 3.825

9.  Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index.

Authors:  Christos Davatzikos; Feng Xu; Yang An; Yong Fan; Susan M Resnick
Journal:  Brain       Date:  2009-05-04       Impact factor: 13.501

10.  Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection.

Authors:  Kelvin K Leung; Matthew J Clarkson; Jonathan W Bartlett; Shona Clegg; Clifford R Jack; Michael W Weiner; Nick C Fox; Sébastien Ourselin
Journal:  Neuroimage       Date:  2009-12-23       Impact factor: 6.556
View more
  23 in total

Review 1.  Diabetes and cognition.

Authors:  Elizabeth Rose Mayeda; Rachel A Whitmer; Kristine Yaffe
Journal:  Clin Geriatr Med       Date:  2014-11-15       Impact factor: 3.076

2.  The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease.

Authors:  Sofie M Adriaanse; Koene R A van Dijk; Rik Ossenkoppele; Martin Reuter; Nelleke Tolboom; Marissa D Zwan; Maqsood Yaqub; Ronald Boellaard; Albert D Windhorst; Wiesje M van der Flier; Philip Scheltens; Adriaan A Lammertsma; Frederik Barkhof; Bart N M van Berckel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-11       Impact factor: 9.236

3.  Magnetization-prepared shells trajectory with automated gradient waveform design.

Authors:  Yunhong Shu; Shengzhen Tao; Joshua D Trzasko; John Huston; Paul T Weavers; Matt A Bernstein
Journal:  Magn Reson Med       Date:  2017-08-21       Impact factor: 4.668

4.  Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease.

Authors:  M V Spampinato; B R Langdon; K E Patrick; R O Parker; H Collins; E Pravata'
Journal:  Neuroradiology       Date:  2016-09-02       Impact factor: 2.804

Review 5.  Imaging markers for Alzheimer disease: which vs how.

Authors:  Giovanni B Frisoni; Martina Bocchetta; Gael Chételat; Gil D Rabinovici; Mony J de Leon; Jeffrey Kaye; Eric M Reiman; Philip Scheltens; Frederik Barkhof; Sandra E Black; David J Brooks; Maria C Carrillo; Nick C Fox; Karl Herholz; Agneta Nordberg; Clifford R Jack; William J Jagust; Keith A Johnson; Christopher C Rowe; Reisa A Sperling; William Thies; Lars-Olof Wahlund; Michael W Weiner; Patrizio Pasqualetti; Charles Decarli
Journal:  Neurology       Date:  2013-07-30       Impact factor: 9.910

6.  Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease.

Authors:  Qiushan Tao; Haihao Zhu; Xi Chen; Robert A Stern; Neil Kowall; Rhoda Au; Jan Krzysztof Blusztajn; Wei Qiao Qiu
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  Diabetes, markers of brain pathology and cognitive function: the Age, Gene/Environment Susceptibility-Reykjavik Study.

Authors:  Chengxuan Qiu; Sigurdur Sigurdsson; Qian Zhang; Maria K Jonsdottir; Olafur Kjartansson; Gudny Eiriksdottir; Melissa E Garcia; Tamara B Harris; Mark A van Buchem; Vilmundur Gudnason; Lenore J Launer
Journal:  Ann Neurol       Date:  2014-01       Impact factor: 10.422

8.  Robust automated detection of microstructural white matter degeneration in Alzheimer's disease using machine learning classification of multicenter DTI data.

Authors:  Martin Dyrba; Michael Ewers; Martin Wegrzyn; Ingo Kilimann; Claudia Plant; Annahita Oswald; Thomas Meindl; Michela Pievani; Arun L W Bokde; Andreas Fellgiebel; Massimo Filippi; Harald Hampel; Stefan Klöppel; Karlheinz Hauenstein; Thomas Kirste; Stefan J Teipel
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 9.  Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease.

Authors:  Benoît Leclerc; Abedelnasser Abulrob
Journal:  ScientificWorldJournal       Date:  2013-02-05

10.  Rare CASP6N73T variant associated with hippocampal volume exhibits decreased proteolytic activity, synaptic transmission defect, and neurodegeneration.

Authors:  Libin Zhou; Kwangsik Nho; Maria G Haddad; Nicole Cherepacha; Agne Tubeleviciute-Aydin; Andy P Tsai; Andrew J Saykin; P Jesper Sjöström; Andrea C LeBlanc
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.